Operation Brain Trauma Therapy
Technical Report,30 Sep 2010,29 Sep 2016
University of Pittsburgh Pittsburgh United States
Pagination or Media Count:
Operation brain trauma therapy OBTT is a groundbreaking, rigorous, multi-center pre-clinical drug biomarker screening consortium for traumatic brain injury TBI. It is supported by 2 closely linked grants from DoD, i.e., WH81XWH-10-1-0623 and OBTT extended studies WH81XWH-14. As requested, this final report is restricted to work on the parent OBTT grant WH81XWH-10-1 -0623. OBTT features testing in rat TBI models at the University of Pittsburgh, the Univ. of Miami, and WRAIR, in micro pig model at Virginia Commonwealth Univ., and biomarker studies at BanyanBiomarkers, Univ. of Florida, and Messina Univ. This grant supported testing of 8 drugs. Screening carried out in 1200 rats included standard outcomes and 5000 biomarker samples. Levetiracetam showed the most benefit in 2 modles. Glibenclamide and amantadine showed model dependent benefit in contusion and penetrating brain injury. The biomarker GFAP performed well. OBTT produced 86 deliverables, including a full issue of J Neorotrauma. The biomarker data were well-received by FDA. OBTT is recognized as a pioneer in the TBI field.
- Medicine and Medical Research